CEA Grants Roche License to Patent that Covers a Process for Synthesis of dsRNA
News Apr 13, 2006
The CEA has announced that its life science division has granted Roche Diagnostics GmbH, (Mannheim, Germany) a non-exclusive license under the patent family EP10618966.
This license concerns some RNAi products that Roche Diagnostics GmbH supplies to its customers in the research reagent field.
This patent family, owned solely by the CEA, covers a process for an enzymatic synthesis of double-stranded RNA based on the transcription of a double-stranded DNA template.
Double-stranded RNA triggers different types of gene silencing named RNA silencing or RNA interference. The application of RNA interference in mammals has the potential to allow therapeutic gene silencing.
In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack. A study found that people who sleep fewer than 7 hours per night have lower blood levels of three physiological regulators, or microRNAs, which influence gene expression and play a key role in maintaining vascular health.